Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Clinical Laboratory Values as Early Indicators of Ebola Virus Infection in Nonhuman Primates.

Reisler RB, Yu C, Donofrio MJ, Warren TK, Wells JB, Stuthman KS, Garza NL, Vantongeren SA, Donnelly GC, Kane CD, Kortepeter MG, Bavari S, Cardile AP.

Emerg Infect Dis. 2017 Aug;23(8):1316-1324. doi: 10.3201/eid2308.170029.

2.

Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges).

Dye JM, Warfield KL, Wells JB, Unfer RC, Shulenin S, Vu H, Nichols DK, Aman MJ, Bavari S.

Viruses. 2016 Apr 8;8(4):94. doi: 10.3390/v8040094.

3.

Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles.

Warfield KL, Dye JM, Wells JB, Unfer RC, Holtsberg FW, Shulenin S, Vu H, Swenson DL, Bavari S, Aman MJ.

PLoS One. 2015 Mar 20;10(3):e0118881. doi: 10.1371/journal.pone.0118881. eCollection 2015.

4.

Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein.

Martins K, Carra JH, Cooper CL, Kwilas SA, Robinson CG, Shurtleff AC, Schokman RD, Kuehl KA, Wells JB, Steffens JT, van Tongeren SA, Hooper JW, Bavari S.

Viral Immunol. 2015 Feb;28(1):62-70. doi: 10.1089/vim.2014.0071.

PMID:
25514232
5.

Euthanasia assessment in ebola virus infected nonhuman primates.

Warren TK, Trefry JC, Marko ST, Chance TB, Wells JB, Pratt WD, Johnson JC, Mucker EM, Norris SL, Chappell M, Dye JM, Honko AN.

Viruses. 2014 Nov 24;6(11):4666-82. doi: 10.3390/v6114666.

6.

Toll-like receptor agonist augments virus-like particle-mediated protection from Ebola virus with transient immune activation.

Martins KA, Steffens JT, van Tongeren SA, Wells JB, Bergeron AA, Dickson SP, Dye JM, Salazar AM, Bavari S.

PLoS One. 2014 Feb 24;9(2):e89735. doi: 10.1371/journal.pone.0089735. eCollection 2014.

7.

A lethal disease model for hantavirus pulmonary syndrome in immunosuppressed Syrian hamsters infected with Sin Nombre virus.

Brocato RL, Hammerbeck CD, Bell TM, Wells JB, Queen LA, Hooper JW.

J Virol. 2014 Jan;88(2):811-9. doi: 10.1128/JVI.02906-13. Epub 2013 Nov 6.

8.

A systematic screen of FDA-approved drugs for inhibitors of biological threat agents.

Madrid PB, Chopra S, Manger ID, Gilfillan L, Keepers TR, Shurtleff AC, Green CE, Iyer LV, Dilks HH, Davey RA, Kolokoltsov AA, Carrion R Jr, Patterson JL, Bavari S, Panchal RG, Warren TK, Wells JB, Moos WH, Burke RL, Tanga MJ.

PLoS One. 2013;8(4):e60579. doi: 10.1371/journal.pone.0060579. Epub 2013 Apr 5.

9.

Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections.

Iversen PL, Warren TK, Wells JB, Garza NL, Mourich DV, Welch LS, Panchal RG, Bavari S.

Viruses. 2012 Nov 6;4(11):2806-30. doi: 10.3390/v4112806.

10.

Key genomic changes necessary for an in vivo lethal mouse marburgvirus variant selection process.

Lofts LL, Wells JB, Bavari S, Warfield KL.

J Virol. 2011 Apr;85(8):3905-17. doi: 10.1128/JVI.02372-10. Epub 2011 Feb 2.

11.

Antiviral activity of serum from the American alligator (Alligator mississippiensis).

Merchant ME, Pallansch M, Paulman RL, Wells JB, Nalca A, Ptak R.

Antiviral Res. 2005 Apr;66(1):35-8.

PMID:
15781130

Supplemental Content

Loading ...
Support Center